scholarly journals Probiotic lactobacilli in formulas and hygiene products for the health of the urogenital tract

2021 ◽  
Vol 9 (5) ◽  
Author(s):  
María Elena Fátima Nader‐Macías ◽  
Priscilla Romina De Gregorio ◽  
Jessica Alejandra Silva
2012 ◽  
Vol 95 (1) ◽  
pp. 31-34 ◽  
Author(s):  
Gregor Reid

Abstract Infections of the urogenital tract in women are extremely common, and there is no evidence of a reduction in incidence. Treatment and preventive strategies have been relatively unchanged for 50 years. The concept of using probiotic lactobacilli or prebiotics that stimulate the growth of protective organisms emerged in the mid-1980s and has led to several strains being tested successfully in women. With the advent of genomic profiling of the healthy vaginal microbiota, an improved understanding of metabolic systems within lactobacilli, and the ability to deliver products in food and supplement forms, the future should see new ways for women to restore and maintain their vaginal health, without the side effects of pharmaceutical agents. Indeed, studies indicate that probiotics can be taken in conjunction with the antibiotics and antifungal agents used to eradicate infections. In the future, probiotics and prebiotics will represent an important adjunct to pharmaceutical and other approaches used to care for feminine health.


2019 ◽  
Vol 22 (07) ◽  
pp. 91-95
Author(s):  
Nehan Bahaaldden Jafar ◽  
Zahraa Talib Ghaleb ◽  
Zainab Hussein Fadhil

2008 ◽  
Vol 4 (4) ◽  
pp. 240-257 ◽  
Author(s):  
Maria Nader-Macias ◽  
Clara de Ruiz ◽  
Virginia Ocana ◽  
Maria Juarez Tomas

Neuroreport ◽  
1994 ◽  
Vol 5 (6) ◽  
pp. 733 ◽  
Author(s):  
Anna M. Leone ◽  
N. Peter Wiklund ◽  
Tomas Hokfelt ◽  
Lou Brundin ◽  
Salvador Moncada

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Caroline Bartolo ◽  
Victoria Hall ◽  
N. Deborah Friedman ◽  
Chloe Lanyon ◽  
Andrew Fuller ◽  
...  

Abstract Background Sodium-glucose co-transporter 2 (SGLT2) inhibitors are novel hypoglycemic agents which reduce reabsorption of glucose at the renal proximal tubule, resulting in significant glycosuria and increased risk of genital mycotic infections (GMI). These infections are typically not severe as reported in large systematic reviews and meta-analyses of the medications. These reviews have also demonstrated significant cardiovascular benefits through other mechanisms of action, making them attractive options for the management of Type 2 diabetes mellitus (T2DM). We present two cases with underlying abnormalities of the urogenital tract in which the GMI were complicated and necessitated cessation of the SGLT2 inhibitor. Case presentations Both cases are patients with T2DM on empagliflozin, an SGLT2 inhibitor. The first case is a 64 year old man with Candida albicans balanitis and candidemia who was found to have an obstructing renal calculus and prostatic abscess requiring operative management. The second case describes a 72 year old man with Candida glabrata candidemia who was found to have prostatomegaly, balanitis xerotica obliterans with significant urethral stricture and bladder diverticulae. His treatment was more complex due to fluconazole resistance and concerns about urinary tract penetration of other antifungals. Both patients recovered following prolonged courses of antifungal therapy and in both cases the SGLT2 inhibitor was ceased. Conclusions Despite their cardiovascular benefits, SGLT2 inhibitors can be associated with complicated fungal infections including candidemia and patients with anatomical abnormalities of the urogenital tract may be more susceptible to these infections as demonstrated in these cases. Clinicians should be aware of their mechanism of action and associated risk of infection and prior to prescription, assessment of urogenital anatomical abnormalities should be performed to identify patients who may be at risk of complicated infection.


1996 ◽  
Vol 63 (3) ◽  
pp. 304-306
Author(s):  
G. Piediferro ◽  
A. Russo ◽  
G. Luciano ◽  
A. Crimi
Keyword(s):  

18 patients with hemospermia were studied and 50% were found to have an infection of the urogenital tract. Other pathologies which came to light were: urethral polyps (11%), BPH (11%), K. prostate (5.6%), urethral varices (5.6%), and interesting prostatovesicular cysts (5.6%); idiopathic in 11% of cases. The proportion and persistence of the hemospermia in some cases would not suggest that this be considered a minor andrological symptom.


1997 ◽  
Vol 24 (2) ◽  
pp. 343-368 ◽  
Author(s):  
Janet E. Tomezsko ◽  
Peter K. Sand
Keyword(s):  

2010 ◽  
Vol 04 (03) ◽  
pp. 348-355 ◽  
Author(s):  
Anna Haukioja

The number of products containing probiotics, viable bacteria with proven health benefits, entering the market is increasing. Traditionally, probiotics have been associated with gut health, and most clinical interest has been focused on their use for prevention or treatment of gastrointestinal infections and diseases; however, during the last decade several investigators have also suggested the use of probiotics for oral health purposes. The aim of this review is to examine potential mechanisms of probiotic bacteria in the oral cavity and summarize observed effects of probiotics with respect to oral health. The review focuses on probiotic lactobacilli and bifidobacteria, genera that are most used in various probiotic products. (Eur J Dent 2010;4:348-355)


Sign in / Sign up

Export Citation Format

Share Document